Authors
Charlotte EL Klaver, Daniel D Wisselink, Cornelis JA Punt, Petur Snaebjornsson, Johannes Crezee, Arend GJ Aalbers, Alexandra Brandt, Andre JA Bremers, Jacobus WA Burger, Hans FJ Fabry, Floris Ferenschild, Sebastiaan Festen, Wilhelmina MU van Grevenstein, Patrick HJ Hemmer, Ignace HJT de Hingh, Niels FM Kok, Gijsbert D Musters, Lotte Schoonderwoerd, Jurriaan B Tuynman, Anthony WH van de Ven, Henderik L van Westreenen, Marinus J Wiezer, David DE Zimmerman, Annette A van Zweeden, Marcel GW Dijkgraaf, Pieter J Tanis, Caroline S Andeweg, Vivian P Bastiaenen, Willem A Bemelman, Jarmila DW van der Bilt, Johanne Bloemen, Frank C den Boer, Djamila Boerma, Daan ten Bokkel Huinink, Walter JA Brokelman, Huib A Cense, Esther CJ Consten, Geert-Jan Creemers, Rogier MPH Crolla, Jan-Willem T Dekker, Jennifer Demelinne, Marc J van Det, Karin K van Diepen, Marjolein Diepeveen, Eino B van Duyn, Esther D van den Ende, Pauline Evers, Anna AW van Geloven, Erwin van der Harst, Jeroen Heemskerk, Joost T Heikens, Daniel A Hess, Bas Inberg, Jan Jansen, Frank WH Kloppenberg, Thomas JM Kootstra, RTJ Kortekaas, Maartje Los, Eva VE Madsen, HCJ van der Mijle, Linda Mol, Peter A Neijenhuis, Simon W Nienhuijs, Loes van den Nieuwenhof, Koen CMJ Peeters, Sebastiaan W Polle, Jolien Pon, Pieter Poortman, Sandra A Radema, Bert van Ramshorst, Philip R de Reuver, Koen P Rovers, Roderick F Schmitz, Nina Sluiter, Dirkje W Sommeijer, DJA Sonneveld, TC van Sprundel, Sanne C Veltkamp, Maarten Vermaas, Victor J Verwaal, Emma Wassenaar, Johannes A Wegdam, Johannes HW de Wilt, Marinke Westerterp, Fennie Wit, Arjen J Witkamp, Karlijn van Woensdregt, Edwin S van der Zaag, Mandy Zournas
Publication date
2019/10/1
Journal
The lancet Gastroenterology & hepatology
Volume
4
Issue
10
Pages
761-770
Publisher
Elsevier
Description
Background
Nearly a quarter of patients with locally advanced (T4 stage) or perforated colon cancer are at risk of developing peritoneal metastases, often without curative treatment options. We aimed to determine the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer.
Methods
This multicentre, open-label trial was done in nine hospitals that specialised in HIPEC in the Netherlands. Patients with clinical or pathological T4N0–2M0-stage tumours or perforated colon cancer were randomly assigned (1:1), with a web-based randomisation application, before resection of the primary tumour, to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy (experimental group) or to adjuvant systemic chemotherapy alone (control group). Patients were stratified by tumour characteristic (T4 or perforation), age (<65 years or ≥65 years), and surgical …
Scholar articles
CEL Klaver, DD Wisselink, CJA Punt, P Snaebjornsson… - The lancet Gastroenterology & hepatology, 2019